GV led a $58.5m round for the heart disease drug developer, which came in the wake of a partnership with another Alphabet subsidiary, Verily.

US-based gene editing technology provider Verve Therapeutics secured $58.5m on Tuesday in a series A round led by GV, a corporate venturing subsidiary of internet technology conglomerate Alphabet. F-Prime Capital, a subsidiary of investment and financial services group Fidelity, also participated in the round, as did venture capital firms Arch Venture Partners and Biomatics Capital. Verve…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.